No abstract

No abstract

Electric vehicles are considered as a new generation of transport to solve the energy crisis. Permanent magnet synchronous motor (PMSM) has been widely used in electric vehicle drive system. A new direct torque control (DTC) for PMSM based on active-disturbance rejection control (ADRC) optimized by improved kernel extreme learning machine (KELM) method is proposed in this paper, which aims to overcome the defects of traditional PI controller. The CKMTOA-KELM optimal regression model is obtained by using chaotic kinetic molecular theory optimization algorithm (CKMTOA) to optimize the kernel parameters and penalty coefficients of KELM regression model. CKMTOA uses chaos search to prevent the algorithm from falling into local optimum and improves the convergence rate by employing adaptive inertia weighting factor. Finally, the ADRC controller embedded the CKMTOA-KELM optimal regression model is analyzed and optimized to improve the dynamic response speed and anti-jamming capability of the system and enhance the robustness of the system. The simulation and experiment results have verified the feasibility and effectiveness of this method.

Lung cancer is the most lethal malignancies with high aggressive and poor prognosis. Until now, the five-year survival rate has not been improved which brings serious challenge to human health. Lung cancer stem cells (LCSCs) serve as the root of cancer occurrence, progression, recurrence, and drug resistance. Therefore, effective anti-cancer agents and molecular mechanisms which could specifically eliminate LCSCs are urgently needed for drug design. In this article, we discovered Olig2 was overexpressed in clinical lung cancer tissues and acted as a transcription factor to regulate cancer stemness by regulating CD133 gene transcription. The results suggested Olig2 could be a promising target in anti-LCSCs therapy and new drugs targeted Olig2 may exhibit excellent clinical results. Furthermore, we verified ACT001, a guaianolide sesquiterpene lactone in phase II clinical trial with excellent glioma remission, inhibited cancer stemness by directly binding to Olig2 protein, inducing Olig2 ubiquitination degradation and inhibiting CD133 gene transcription. All these results suggested that Olig2 could be an excellent druggable target in anti-LCSCs therapy and lay a foundation for the further application of ACT001 in the treatment of lung cancer in clinical.